Duchenne Muscular Dystrophy

FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
Endpoints
Sarepta Therapeutics
FDA
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Flag link:
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Researchers Use CRISPR to Treat Duchenne Muscular Dystrophy in Dogs
Researchers Use CRISPR to Treat Duchenne Muscular Dystrophy in Dogs
BioSpace
DMD
Duchenne Muscular Dystrophy
CRISPR
drug development
Flag link:
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
CP Wire
Pfizer
domagrozumab
Duchenne Muscular Dystrophy
Flag link:
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
Pfizer
domagrozumab
Duchenne Muscular Dystrophy
Flag link:
Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?
Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?
Xtalks
Mallinckrodt
MNK-1411
Duchenne Muscular Dystrophy
clinical trials
Flag link:
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
clinical hold
gene therapy
Flag link:
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
CP Wire
edasalonexent
clinical trials
Duchenne Muscular Dystrophy
Flag link:
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Flag link:
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Xconomy
Summit Therapeutics
ezutromid
clinical trials
Duchenne Muscular Dystrophy
Flag link:
[video/transcript]Sarepta Therapeutics Could Be Onto Something Big
[video/transcript]Sarepta Therapeutics Could Be Onto Something Big
Motley Fool
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Early access to Santhera’s DMD therapy Raxone extended in the UK
Early access to Santhera’s DMD therapy Raxone extended in the UK
Pharma Times
UK
Santhera
Raxone
Duchenne Muscular Dystrophy
Flag link:
3 patients add $2.5B to Sarepta's value
3 patients add $2.5B to Sarepta's value
Biopharma Dive
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’
With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’
Stat
Sarepta Therapeutics
Duchenne Muscular Dystrophy
clinical trials
Flag link:
As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy
As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy
Xconomy
Duchenne Muscular Dystrophy
Solid Biosciences
Sarepta Therapeutics
SGT-001
Flag link:
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
Flag link:
Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment
Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment
CP Wire
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Flag link:
Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Flag link:
Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
Endpoints
Daiichi Sankyo
Duchenne Muscular Dystrophy
DS-5141
Flag link:
Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)
Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)
CP Wire
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
clinical trials
Flag link:

Pages